![SonomaEye-full-color-vector[2].png](https://static.wixstatic.com/media/bed00b_da20b9cc704044b0b048ac8ef9190470~mv2_d_3024_2195_s_2.png/v1/fill/w_177,h_123,al_c,q_85,usm_0.66_1.00_0.01,enc_auto/SonomaEye-full-color-vector%5B2%5D.png)
Thank you for your submission!
Anatomical Subtype Stratification for Evaluating the Safety and Efficacy of CLS-TA in Noninfectious Uveitis-Related Macular Edema: Insights from the P
Milan Shah
Presenter:
Milan Shah, Quan Nguyen, Christopher R Henry
Authors:
Affiliation:
1. Ophthalmology, Midwest Eye Institute, Carmel, Indiana, USA
2. Byers Eye Institute, Stanford University School of Medicine, Palo Alto, California, USA
3. Retina Consultants of Texas, Houston, TX, USA.
Purpose: This study investigates the effectiveness of CLS-TA, a proprietary suprachoroidal injectable suspension of triamcinolone acetonide, in treating macular edema (ME) associated with noninfectious uveitis (NIU), categorized by distinct anatomic subtypes.
Methods: The phase 3 PEACHTREE trial enrolled patients with ME linked to NIU of any etiology and anatomic subtype. Post-hoc analyses were conducted, stratifying participants based on the specific anatomic subtype of uveitis (anterior, intermediate, posterior, and panuveitis).
Results: Over 24 weeks, patients administered CLS-TA at baseline and week 12 exhibited notable improvements across all anatomic subtypes. Mean increases in best-corrected visual acuity (BCVA) ranged from +12.1 to +15.9 letters, central subfield thickness (CST) showed improvement ranging from −120.1 μm to −189.0 μm, and intraocular pressure (IOP) changes ranged from +0.5 to +3.1 mmHg. Overall, adverse event reports were consistent across subtypes.
Conclusion: Regardless of the uveitic anatomic subtype, individuals treated with CLS-TA for ME associated with NIU demonstrated clinical benefits, accompanied by a comparable safety profile.